Evidence map›Paper›PMID 33679411›Full record

ArticleFrontiers in pharmacology2021

Isorhamnetin Inhibits Human Gallbladder Cancer Cell Proliferation and Metastasis via PI3K/AKT Signaling Pathway Inactivation.

Tianyu Zhai, Xiaoyu Zhang, Zhenyu Hei, Longyang Jin, Chao Han, Audrey Tsznam Ko, Xiaofeng Yu, Jiandong Wang

Erratum issuedOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 22 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 1 pooled it
7.9field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Advanced biomedical research · 2025
    Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Isorhamnetin: what is theFrontiers in pharmacology · 2024
    Review
  16. Article
  17. Article
  18. Article
  19. Potential ofMolecules (Basel, Switzerland) · 2022
    Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Tianyu ZhaiShanghai Key Laboratory of Biliary Tract Disease Research, Shanghai, China.
Xiaoyu ZhangDepartment of General Surgery, Xinhua Hospital, Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Zhenyu HeiDepartment of General Surgery, Xinhua Hospital, Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Longyang JinDepartment of Colorectal Surgery, The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Chao HanDepartment of General Surgery, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Audrey Tsznam KoFaculty of Medicine, Imperial College London, London, United Kingdom.
Xiaofeng YuDepartment of General Surgery, People's Hospital of Gaoxin District, Suzhou, China.
Jiandong WangShanghai Key Laboratory of Biliary Tract Disease Research, Shanghai, China.
Shanghai Jiao Tong University · CNImperial College London · GBSun Yat-sen University · CNXinHua Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gallbladder cancer (GBC) is the most common biliary tract tumor with a poor prognosis. Isorhamnetin is a flavonoid compound extracted from

Indexed as

apoptosisgallbladder cancerisorhamnetinPI3K/akt pathwaytumor progression

Identifiers

PMID33679411
PMCPMC7927673
OpenAlexW4237295171

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.